Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (36)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Handelsman, D. J.
Right arrow Articles by Conway, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Handelsman, D. J.
Right arrow Articles by Conway, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 15, No. 3, 672-679, March 2000
© 2000 European Society of Human Reproduction and Embryology

Oestradiol enhances testosterone-induced suppression of human spermatogenesis

David J. Handelsman1, S. Wishart and Ann J. Conway

Department of Andrology, Concord Hospital, Department of Medicine, University of Sydney, Sydney, NSW 2006, Australia

The aim of this study was to determine for the first time in humans, the efficacy of adding a low dose oestradiol to a suboptimally suppressive testosterone dose in a depot hormonal regimen to suppress spermatogenesis in healthy eugonadal men. Twenty-six healthy men were randomized into groups that were treated by a single subdermal implantation of either 600 mg testosterone alone (T; n = 11) or together with 10 mg (TE10, n = 7) or 20 mg (TE20, n = 8) oestradiol. Administration of oestradiol produced a dose-dependent increase in peak plasma oestradiol at 1 month and prolonged suppression of plasma LH and FSH leading to significantly enhanced suppression of sperm output. Despite the augmented spermatogenic suppression, there was no significant difference in the proportions achieving azoospermia (6/26, 23%) or severe oligozoospermia (<1 or <3x106 spermatozoa per ml, 7/26, 27%) and overall these proportions were inadequate to provide reliable contraception according to the standards identified in World Health Organization male contraceptive efficacy studies. Total and free testosterone remained within the eugonadal reference range for young men throughout the study. While the lower oestradiol dosage had minimal spermatogenic suppression effects, the higher dose produced dose-limiting adverse effects of androgen deficiency and/or oestrogen excess between the fourth and sixth month of the study. This appeared to be due to the unexpectedly prolonged, low concentration of oestradiol release from the oestradiol implants. There were no significant treatment-related changes in body composition, lipids, prostate-specific antigen, haematological or biochemical variables. Thus oestradiol has a low therapeutic window and dose-limiting side-effects at dosages that fail to achieve the uniform azoospermia required of an effective male hormonal contraceptive regimen.

Key words: family planning/male contraception/oestradiol/spermatogenesis/testosterone

1 To whom correspondence should be addressed at: Department of Medicine (D02), University of Sydney, Sydney, NSW 2006, Australia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
A. Jones, J. Chen, D. J. Hwang, D. D. Miller, and J. T. Dalton
Preclinical Characterization of a (S)-N-(4-Cyano-3-Trifluoromethyl-Phenyl)-3-(3-Fluoro, 4-Chlorophenoxy)-2-Hydroxy-2-Methyl-Propanamide: A Selective Androgen Receptor Modulator for Hormonal Male Contraception
Endocrinology, January 1, 2009; 150(1): 385 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
L. P Ly and D. J Handelsman
Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays
Eur. J. Endocrinol., March 1, 2005; 152(3): 471 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
B.M. Brady, M. Walton, N. Hollow, A.T. Kicman, D.T. Baird, and R.A. Anderson
Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception
Hum. Reprod., November 1, 2004; 19(11): 2658 - 2667.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. Shetty, C. C. Y. Weng, O. U. Bolden-Tiller, I. Huhtaniemi, D. J. Handelsman, and M. L. Meistrich
Effects of Medroxyprogesterone and Estradiol on the Recovery of Spermatogenesis in Irradiated Rats
Endocrinology, October 1, 2004; 145(10): 4461 - 4469.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Kelleher, A. J. Conway, and D. J. Handelsman
Blood Testosterone Threshold for Androgen Deficiency Symptoms
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3813 - 3817.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Meier, P. Y. Liu, L. P. Ly, J. de Winter-Modzelewski, M. Jimenez, D. J. Handelsman, and M. J. Seibel
Recombinant Human Chorionic Gonadotropin But Not Dihydrotestosterone Alone Stimulates Osteoblastic Collagen Synthesis in Older Men with Partial Age-Related Androgen Deficiency
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3033 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Turner, A. J. Conway, M. Jimenez, P. Y. Liu, E. Forbes, R. I. McLachlan, and D. J. Handelsman
Contraceptive Efficacy of a Depot Progestin and Androgen Combination in Men
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4659 - 4667.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. A. Anderson and D. T. Baird
Male Contraception
Endocr. Rev., December 1, 2002; 23(6): 735 - 762.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R.A. Anderson, Z.M. van der Spuy, O.A. Dada, S.K. Tregoning, P.M. Zinn, O.A. Adeniji, T.A. Fakoya, K.B. Smith, and D.T. Baird
Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone
Hum. Reprod., November 1, 2002; 17(11): 2869 - 2877.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. A. Anderson, D. Kinniburgh, and D. T. Baird
Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3640 - 3649.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Y. Liu, S. M. Wishart, and D. J. Handelsman
A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Recombinant Human Chorionic Gonadotropin on Muscle Strength and Physical Function and Activity in Older Men with Partial Age-Related Androgen Deficiency
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3125 - 3135.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. Kinniburgh, H. Zhu, L. Cheng, A.T. Kicman, D.T. Baird, and R.A. Anderson
Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men
Hum. Reprod., June 1, 2002; 17(6): 1490 - 1501.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
H.M. Behre, S. Kliesch, B. Lemcke, S. von Eckardstein, and E. Nieschlag
Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone
Hum. Reprod., December 1, 2001; 16(12): 2570 - 2577.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. P. Ly, M. Jimenez, T. N. Zhuang, D. S. Celermajer, A. J. Conway, and D. J. Handelsman
A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Transdermal Dihydrotestosterone Gel on Muscular Strength, Mobility, and Quality of Life in Older Men with Partial Androgen Deficiency
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4078 - 4088.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. O'Donnell, K. M. Robertson, M. E. Jones, and E. R. Simpson
Estrogen and Spermatogenesis
Endocr. Rev., June 1, 2001; 22(3): 289 - 318.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.